Cargando…
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
BACKGROUND: Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting...
Autores principales: | Cairns, Junmei, Ingle, James N., Kalari, Krishna R., Shepherd, Lois E., Kubo, Michiaki, Goetz, Matthew P., Weinshilboum, Richard M., Wang, Liewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448248/ https://www.ncbi.nlm.nih.gov/pubmed/30944027 http://dx.doi.org/10.1186/s13058-019-1130-3 |
Ejemplares similares
-
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020) -
Polymorphisms in lncRNA MIR2052HG and susceptibility to breast cancer in Chinese population
por: Yang, Hui, et al.
Publicado: (2021) -
SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1
por: Cairns, Junmei, et al.
Publicado: (2017) -
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2
por: Dudenkov, Tanda M., et al.
Publicado: (2019) -
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)